The first directly dated wildcat bones found in Ireland have been identified, confirming that the species inhabited the island more than 5,500 years ago.

Alongside getting behind the Sixers and taking in the odd Union game, sports lovers in Philadelphia are firmly behind the […]

Dana Briggs, 70, had charges dropped after being accused of assaulting an agent during a protest at an Illinois ICE facility

Current and former Department of Government Efficiency (DOGE) staffers are growing increasingly concerned that the work they did slashing government programs and eliminating jobs will come back to hau...

The Trump administration's "One Big Beautiful Bill" excludes nursing from graduate degree programs deemed as 'professional.' The move impacts loan funding, healthcare delivery, and patient care access...

The agency this week quietly changed its official language to suggest vaccines may cause autism, a claim that scientists say has no basis in evidence

"This is a one-of-a-kind system with an incredibly rare orbital period."

Commercial autologous anti-CD19 chimeric antigen receptor-T cell therapies are effective in B cell malignancies and autoimmune diseases but are limited by personalized manufacturing, high costs and the risk from random chimeric antigen receptor insertion into the genome. To overcome these challenges, we developed YTS109, a hypoimmune allogeneic T cell product engineered using CRISPR–Cas9 to knock out TRAC, PD1, HLA-A, HLA-B and CIITA, with a CD19-targeting synthetic TCR and antigen receptor (STAR) precisely integrated into the TRAC locus to enable physiological, TCR-like signaling. As part of a multi-disease cohort trial, this article includes all enrolled five patients with severe, refractory systemic lupus erythematosus (SLE) complicated by lupus nephritis, who received lymphodepletion followed by YTS109 at 3 × 106 STAR⁺ T cells per kg body weight. Primary endpoints were safety and SLE responder index 4 at month (M) 3. Secondary endpoints included clinical remission and quality-of-li